/

IPN.PA

IPSENClosed

145.60+3.00 +2.10%EUR

Paris · as of Oct 14, 11:35 ET · 15m delay

Open

142.20

Prev close

142.60

Day range

141.60145.60

52-week range

112.70174.00

Volume

163.92K1.61×

Mkt cap

12.00B

P/E ttm

23.56

Fwd P/E

10.39

EPS ttm

6.18

Div yield

1.12%

Earnings

Jul 30, 2026

From 52w high

−16.32%

Price Chart

Yahoo Finance · delayed

IPN.PAOct 13, 2026O 144.40H 145.80L 141.80C 142.60−1.50 (−1.04%)Vol 99.15K

SMA 50155.43
SMA 200155.14

1Y change +25.31% since Oct 14, 2025 close548 bars loadedTimes in Europe/ParisDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

IPN.PA IPSEN · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: +1.42%
1 month: −9.23%
3 months: −9.97%
6 months: −13.58%
Year to date: +19.83%
1 year: +24.00%

Valuation & ownership

Market cap: 12.00B
Enterprise value: 10.99B
P/E (ttm): 23.56
Forward P/E: 10.39
PEG ratio: 0.49
Price / book: 2.55
Price / sales (ttm): 2.80
EV / EBITDA: 7.36
EPS (ttm): 6.18
EPS (forward): 14.01
Beta (5y monthly): 0.35
Dividend yield: 1.12%
Payout ratio: 25.89%
Shares outstanding: 82.42M
Float: 29.97M
Short % of float: —
Short ratio (days): —
Held by insiders: 57.64%
Held by institutions: 21.72%
Avg volume (3m): 101.71K
50-day average: 155.43
200-day average: 155.65
52-week change: +24.00%
S&P 500 52-week: +15.71%

Technicals (daily)

RSI (14): 39.2
vs 50-day SMA: −8.25%
vs 200-day SMA: −8.08%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▲ above
ATR (14) % of price: 2.68%
Realised vol (20d, ann.): 30.1%
From 52-week high: −18.05%
From 52-week low: +26.53%

ANR

Analyst Consensus

14 analysts

Consensus

Hold

2.64 on a 1 (strong buy) – 5 (sell) scale

Mean target

164.29

+12.83% implied

Low 130.00Median 162.50High 235.00

Recommendation trend

Now5 / 6 / 3
1m ago

DES

About IPSEN

Yahoo Finance profile

Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience in North America, Europe, and internationally. It engages in the development of Somatuline for neuroendocrine tumors and acromegaly indications; and Dysport for motor muscular disorders and medical aesthetics indications; and Decapeptyl for advanced metastatic prostate cancer, uterine fibroids, central precocious puberty, endometriosis, female infertility, and early-stage breast cancer in combination with hormone therapy. The company also develops Cabometyx for renal cell carcinoma, second line hepatocellular carcinoma, differentiated thyroid cancer, and neuroendocrine tumors; Onivyde for second-line metastatic pancreatic cancer; and Bylvay for the treatment of progressive familial intrahepatic cholestasis and cholestatic pruritus in patients with both PFIC and Alagille syndrome. In addition, it is involved in the development of Iqirvo for the second line treatment for primary biliary cholangitis; Sohonos for the treatment to reduce new, abnormal bone formation in soft and connective tissues, in people living with ultra-rare bone disease, and fibrodysplasia ossificans progressiva; and IPN60340 in Phase I/II clinical trial for first line acute myeloid leukemia indications. Further, the company develops Tazverik + rituximab and lenalidomide in Phase III clinical trials for second line follicular lymphoma indications; Tovorafenib in Phase III clinical trials for first line pediatric low-grade gliomas indications; and IPN01194, IPN01195, IPN60300, and IPN01203 in Phase I for solid tumors indications; and IPN10200 in Phase II clinical trials for aesthetic and therapeutic indications. Ipsen S.A. was founded in 1929 and is headquartered in Paris, France.

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 5,535
Headquarters: Paris, France
Website

SEAS

Seasonality · IPN.PA

2007–2026 · monthly returns

Strongest month Apr +5.49%Weakest month Jun −3.44%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	15.6	20.0	-2.8	4.1	-6.2	7.8	-0.9	-2.5	-12.9	2.5			+22.4%
2025	7.7	-6.7	-4.3	-4.0	1.6	-2.5	2.6	11.9	-2.1	7.2	2.1	-4.3	+7.5%
2024	-0.8	-4.9	8.3	3.4	5.7	-5.1	-9.2	5.5	0.7	1.3	-2.2	1.2	+2.6%
2023	-4.1	12.1	-6.1	8.4	-1.7	1.9	4.0	4.5	3.7	-10.2	-7.2	4.3	+7.4%
2022	7.2	20.8	8.7	-12.9	-5.6	-3.4	9.7	-3.3	-0.7	9.6	3.1	-6.2	+24.8%
2021	6.1	-1.9	3.5	10.0	2.9	6.0	2.7	-6.0	-2.5	8.3	-3.6	-6.5	+18.6%
2020	-15.2	-12.5	-19.5	43.6	4.4	7.0	8.0	6.2	3.2	-12.7	3.5	-16.0	−14.1%
2019	-2.5	10.5	0.5	-14.8	2.7	12.3	-13.6	-7.8	-8.9	9.6	7.3	-22.9	−30.0%
2018	13.4	7.0	4.4	6.6	0.9	-1.0	5.8	7.1	-4.9	-15.3	-7.3	-0.7	+13.3%
2017	4.4	16.9	11.8	14.0	5.1	6.8	-9.7	4.2	-0.4	-7.7	-1.3	-2.8	+44.9%
2016	-12.9	-0.2	-4.8	4.7	7.3	-2.2	5.3	-0.2	7.3	0.8	1.6	7.4	+12.6%
2015	4.9	0.7	-3.1	16.5	-5.1	1.8	18.3	2.1	-7.3	3.6	5.8	0.4	+41.9%
2014	-9.4	0.0	-4.5	7.6	12.6	-8.3	0.6	9.5	7.1	0.8	8.2	1.3	+25.1%
2013	13.6	2.5	5.2	-2.8	3.0	1.4	6.5	-7.3	1.5	13.7	7.2	-0.8	+50.9%
2012	-7.4	-10.1	1.5	-1.8	2.7	-5.4	-1.6	-1.1	-0.3	4.9	9.8	4.2	−6.1%
2011	11.8	-3.3	2.5	4.4	7.8	-14.1	-7.1	3.1	-3.5	5.5	-9.9	12.8	+6.2%
2010	0.4	-4.1	-3.0	-1.0	-3.5	-27.7	2.1	5.6	-9.8	4.1	-9.0	-0.8	−41.1%
2009	9.5	-1.5	-4.0	7.2	6.0	-5.5	3.8	6.8	8.5	-7.3	4.9	6.6	+38.5%
2008	-9.8	7.4	-10.0	9.2	10.0	-24.7	5.7	7.7	-13.9	-6.8	-11.9	7.1	−32.1%
2007	-0.8	-1.3	6.5	5.9	0.1	-2.6	2.3	-0.8	4.9	-2.8	-1.5	6.5	+17.1%

IPN.PA

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

IPN.PA

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About IPSEN

Seasonality · IPN.PA

Insider Activity · IPN.PA

Congress Trades · IPN.PA

Investors Holding IPN.PA

Investors Holding IPN.PA

Congress Trades · IPN.PA

Insider Activity · IPN.PA

Seasonality · IPN.PA

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About IPSEN

Financial Snapshot

Earnings & Dividends

News